On May 26, WuXi Biologics rose 4.34% in regular trading, trading at HK$33.54 per share, with trading volume of HK$398 million.

On the news front, WuXi Biologics announced that its board resolved on May 24 to exercise the general buyback mandate, authorizing the company to repurchase shares on the open market at a total price not exceeding USD 400 million. The mandate permits the buyback of up to 407 million shares, representing 10% of the total issued shares as of the annual general meeting date. The company explicitly stated that the current share trading price does not reflect its intrinsic value or actual business prospects, and that the buyback plan demonstrates strong confidence in its future business development outlook.

The buyback authorization was originally proposed on May 19, when the board recommended granting a general mandate to repurchase up to 10% of issued shares on the Hong Kong Stock Exchange. Based on approximately 4.14 billion shares outstanding, the company noted it would not proceed with repurchases that could have a material adverse impact on its financial or operational position.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)